Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 324 participants.
Also called NCT03030235
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 324 participants
- Sponsor
- Registry
-
NCT03030235
-
- Main results
- The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
- Other papers using this trial's data
- Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF
- Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The PRESERVED-HF Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03030235. Randomized; quadruple masking; primary purpose treatment. Start 2017-03-01 (actual); primary completion 2021-08-13 (actual). Results posted on 2022-10-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
- Acronym
- PRESERVED-HF
- Condition
- Chronic Heart Failure With Preserved Systolic Function
- Intervention (Drug)
- Dapagliflozin 10Mg Oral Tablet
- Intervention (Drug)
- Dapagliflozin matching placebo
- Lead sponsor
- Saint Luke's Health System
Record details
- Record id
cardio:ct-nct03030235- Content hash
cfb070eb77b69668a79554ae1e399d476543f5256a9ef5d24420d2dc8e8b0ddb